<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284722</url>
  </required_header>
  <id_info>
    <org_study_id>1126/2019</org_study_id>
    <nct_id>NCT04284722</nct_id>
  </id_info>
  <brief_title>Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery</brief_title>
  <official_title>Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kepler University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kepler University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of peri-operative continuation of oral metformin therapy on the
      incidence of perioperative hyperglycemia compared to standard preoperative cessation of oral
      metformin therapy 24h before surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical procedures cause metabolic stress and can impair glucose control especially in
      patients with diabetes mellitus, which often results in peri-operative hyperglycemia.
      Peri-operative hyperglycemia is associated with impaired wound healing, secondary wound
      infections, endothelial dysfunction, sepsis, prolonged hospital stay and higher mortality.

      Metformin is still the first line treatment in patients with type 2 diabetes mellitus.

      Historically it has been stopped before surgery due to fear of hypoglycemia and metformin
      induced lactic acidosis. However recent studies have suggested that perioperative
      continuation of metformin might be safe and patients could benefit from more stable
      preoperative blood sugar levels.

      Prospective studies evaluating the benefit of continuing oral metformin therapy in the
      perioperative period are rare.

      The investigators plan to conduct a prospective, randomized-controlled, unblinded clinical
      trial where patients with type II diabetes mellitus and oral metformin therapy undergoing
      non-cardiac surgery will be randomized in either an interventional group or a control group.
      In the interventional group patients will be instructed to continue their regular metformin
      dose even on the day of surgery, in contrast to the control group, where the patients will be
      instructed to stop taking metformin 24h prior to surgery.

      All other oral anti-diabetic drugs will be paused according to the local anesthesia
      guidelines.

      The investigators plan to evaluate whether or not continuation of metformin can reduce the
      incidence of perioperative hyperglycemia and whether or not it is associated with elevation
      of blood lactate levels.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Perioperative Hyperglycemia</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>blood glucose &gt;180mg/dl (10mmol/l) and/or necessity of additive administration of insulin s.c. during the time frame</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative blood glucose control</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>mean plasma glucose at 4 defined dates: 24h pre-op, intra-op, 2hours post-op and 24h post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence hypoglycemia</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>blood sugar levels &lt; 70mg/dl (3.9mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative lactate levels</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>mediane lactate levels at 4 defined dates: 24h pre-op, intra-op, 2 hours post-op and 24h post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperlactatemia</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>blood lactate values &gt;4mmol/L at least at one of 4 measurement dates: 24h pre-op, intra-op, 2 hours post-op, 24 hours post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative renal function</measure>
    <time_frame>24 hours pre-op until 24 hours post-op</time_frame>
    <description>median serum-creatinine value at 24h pre-op and 24h post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Duration</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>median time period from day of surgery until discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>In-Hospital mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Metformin</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Hyperlactatemia</condition>
  <arm_group>
    <arm_group_label>Metformin +</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin -</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals</description>
    <arm_group_label>Metformin +</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-99 years

          -  Diabetes Mellitus Typ 2

          -  Oral metformin therapy

          -  Non cardiac-surgery

          -  Informed consent

        Exclusion Criteria:

          -  Insulin therapy

          -  Ambulatory surgery

          -  Preoperative therapy with glucocorticoids (prednisolon or equivalent â‰¥ 5mg/day for
             more than 7 days)

          -  Planned postoperative ICU-stay

          -  Advanced renal insufficiency (eGFR &lt; 45ml/kg/min)

          -  Advanced liver cirrhosis or failure (Child-Pugh B or C)

          -  Alcohol abuse

          -  Pregnancy,

          -  Perioperative administration of contrast dye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Meier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kepler University Hospital -Dpt. of Anesthesiology &amp; Intensive Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Noitz, MD</last_name>
    <phone>+43 (0)5 7680 83 - 78171</phone>
    <email>matthias.noitz@kepleruniklinikum.at</email>
  </overall_contact>
  <reference>
    <citation>Hulst AH, Polderman JAW, Ouweneel E, Pijl AJ, Hollmann MW, DeVries JH, Preckel B, Hermanides J. Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 Mar;20(3):749-752. doi: 10.1111/dom.13118. Epub 2017 Oct 13.</citation>
    <PMID>28940961</PMID>
  </reference>
  <reference>
    <citation>Gasanova I, Meng J, Minhajuddin A, Melikman E, Alexander JC, Joshi GP. Preoperative Continuation Versus Interruption of Oral Hypoglycemics in Type 2 Diabetic Patients Undergoing Ambulatory Surgery: A Randomized Controlled Trial. Anesth Analg. 2018 Oct;127(4):e54-e56. doi: 10.1213/ANE.0000000000003675.</citation>
    <PMID>30044293</PMID>
  </reference>
  <reference>
    <citation>Kuzulugil D, Papeix G, Luu J, Kerridge RK. Recent advances in diabetes treatments and their perioperative implications. Curr Opin Anaesthesiol. 2019 Jun;32(3):398-404. doi: 10.1097/ACO.0000000000000735. Review.</citation>
    <PMID>30958402</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.</citation>
    <PMID>20393934</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kepler University Hospital</investigator_affiliation>
    <investigator_full_name>Jens Meier</investigator_full_name>
    <investigator_title>Prof. Jens Meier, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hyperlactatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

